News - 20 Jun 2018
OHSU Knight Cancer Institute Director Brian J. Druker, M.D., has been awarded the 2018 Tang Prize in Biopharmaceutical Science for his pioneering role in shaping the fields of precision medicine and...
News - 13 Nov 2015
Two young technologists from the Technological Institute of Chihuahua, in the north of Mexico, developed a device that can measure glucose in blood through the urine on the toilet, it activates via...
News - 23 Oct 2015
A new conference helping doctors navigate one of the most important scientific questions faced by the cancer community could help improve survival rates for patients.
News - 17 Sep 2014
The human brain is capable of a neural workaround that compensates for the buildup of beta-amyloid, a destructive protein associated with Alzheimer's disease, according to a new study led by...
News - 30 Jan 2014
NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services, announced today that it has validated and launched a series of NeoTYPE cancer profiling tests covering...
News - 7 Jan 2014
Blueprint Medicines today announced the completion of a $25 million Series B financing. The oncology-focused investor, Nextech Invest Ltd., led the round, which also included founding investors Third...
News - 11 Mar 2011
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported fourth-quarter...
News - 27 May 2010
At a meeting today of the United States Pharmacopeia's (USP) Nomenclature Expert Committee, the Consortium for the Advancement of Patient Safety (CAPS) presented results of an independent study...
News - 10 Nov 2009
In research that sheds light on the perils of yo-yo dieting and repeated bouts of sugar-bingeing, researchers from The Scripps Research Institute have shown in animal models that cycling between...
News - 22 Feb 2005
Researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) have found an explanation for why some lung cancers stop responding to the drugs erlotinib (Tarceva) and gefitinib (Iressa).